Arntl Antibody

What is the tissue expression profile of ARNTL/BMAL1?

ARNTL expression has been documented across multiple tissues, with particular emphasis on specific regions. Based on published literature and experimental validation, ARNTL is expressed in:

• Brain tissue, supported by multiple studies (PubMed IDs: 9144434, 14702039)

• Brain and skin tissues (PubMed ID: 15489334)

• Fetal brain tissue (PubMed ID: 9079689)

• Left lobe of thyroid gland

• Heart tissue (validated in mouse and rat models)

Understanding the tissue-specific expression patterns is essential for experimental design, particularly when selecting appropriate positive controls for antibody validation procedures and interpreting experimental results in different tissue contexts.

What cellular localization pattern should be expected when using an ARNTL antibody?

ARNTL is predominantly expressed in the nucleus, which aligns with its function as a transcription factor involved in circadian rhythm regulation . When using immunohistochemistry or immunofluorescence techniques, positive nuclear staining is the expected pattern. Some researchers have questioned the significance of nuclear staining observed in brain tissue samples, which has been confirmed as the correct localization pattern . If cytoplasmic staining is observed, additional validation steps should be performed to confirm specificity, as this may represent non-specific binding or an unexpected biological phenomenon worth investigating further.

Which species can be reliably detected with commonly available ARNTL antibodies?

Commercial ARNTL antibodies typically demonstrate reactivity with:

• Human samples

• Mouse tissues

• Rat tissues

The cross-species reactivity is valuable for comparative studies and translational research. While some antibodies have not been specifically validated for reactivity with other species like goat, there is potential for cross-reactivity due to sequence homology . When working with non-validated species, preliminary testing with appropriate positive controls is strongly recommended before proceeding with full experimental protocols.

How does ARNTL contribute to cancer pathogenesis, and what mechanisms should researchers focus on?

Current studies indicate that ARNTL plays an anticancer role and is often downregulated in certain cancer types . In tongue squamous cell carcinoma (TSCC), ARNTL overexpression has been shown to:

• Inhibit proliferation and colony formation of cancer cells

• Induce apoptosis in cancer cells

• Reduce cell migration and invasion capabilities

The anticancer effects appear to be mediated through the regulation of autophagy, as demonstrated by electron microscopy observations of increased autophagolysosomes in ARNTL-overexpressing cells . When autophagy was inhibited using agents like Auto and Baf, the anticancer effects of ARNTL were attenuated, suggesting a mechanistic link between ARNTL, autophagy, and cancer suppression .

Researchers should therefore focus on:

• Changes in autophagic flux when manipulating ARNTL expression

• Interactions between ARNTL and key autophagy regulatory proteins

• The impact of circadian disruption on ARNTL-mediated tumor suppression

What is the relationship between ARNTL/BMAL1 polymorphisms and disease susceptibility?

The relationship between ARNTL genetic variants and disease susceptibility remains controversial and requires careful experimental design and analysis. A study investigating the association between ARNTL polymorphisms (specifically rs3789327) and multiple sclerosis (MS) found no statistically significant association .

This contradicted previous findings by Lavtar et al. in a Slavic population, highlighting the importance of:

• Maintaining rigorous quality control in genotyping studies

• Ensuring Hardy-Weinberg equilibrium in control populations

• Achieving adequate statistical power (>80%) to detect previously reported effect sizes

• Considering population-specific differences in genetic associations

Researchers investigating ARNTL polymorphisms should be cautious about small effect sizes (ORs of 1.10-1.15) that may require larger sample sizes to detect reliably .

How can researchers address contradictory findings in ARNTL antibody staining patterns?

When facing contradictory ARNTL antibody staining results, researchers should implement a systematic validation approach:

• Verify antibody specificity through:

  • Western blot analysis with positive and negative controls

  • RNA interference to confirm signal reduction upon target knockdown

  • Testing multiple antibodies targeting different epitopes of ARNTL

• Evaluate technical variables:

  • Fixation methods (different fixatives can affect epitope accessibility)

  • Antigen retrieval protocols

  • Blocking reagents to minimize non-specific binding

  • Incubation conditions (time, temperature, antibody concentration)

• Consider biological variables:

  • Circadian time point of sample collection (ARNTL expression follows circadian patterns)

  • Tissue-specific post-translational modifications

  • Potential splice variants with altered epitope presentation

What are the optimal storage and handling protocols for ARNTL antibodies?

For maximum stability and performance of ARNTL antibodies, follow these evidence-based storage protocols:

• Long-term storage: Maintain at -20°C for up to one year from the date of receipt for lyophilized antibodies

• After reconstitution: Store at 4°C for up to one month, or aliquot and freeze at -20°C for up to six months

• Avoid repeated freeze-thaw cycles, as they can lead to denaturation and reduced antibody performance

• For working solutions, prepare fresh dilutions on the day of experimentation when possible

Improper storage can lead to inconsistent results and false negatives, particularly in sensitive applications like immunohistochemistry. Researchers should maintain detailed records of antibody lot numbers, purchase dates, and reconstitution dates to track potential sources of experimental variability.

What experimental design considerations are critical when using ARNTL antibodies in circadian rhythm studies?

When designing experiments using ARNTL antibodies for circadian rhythm research:

• Temporal sampling strategy:

  • Collect samples at multiple circadian time points (minimum 4-6 points across 24 hours)

  • Ensure consistent timing of sample collection between experimental groups

  • Document lighting conditions and time since light/dark transitions

• Controls and validation:

  • Include samples from ARNTL knockout models when available

  • Compare with parallel measurements of other clock genes (CLOCK, PER, CRY)

  • Consider using tissues with known robust ARNTL rhythms (e.g., liver) as positive controls

• Data analysis:

  • Apply appropriate circadian statistical methods (cosinor analysis, JTK_CYCLE)

  • Account for potential phase shifts between tissues/experimental conditions

  • Consider normalization to housekeeping genes stable across circadian time

How should researchers troubleshoot weak or non-specific signals in Western blot applications with ARNTL antibodies?

When facing weak or non-specific signals in Western blot analysis with ARNTL antibodies:

• Sample preparation optimization:

  • Ensure complete protein denaturation (verify heating time/temperature)

  • Include protease inhibitors in lysis buffers to prevent degradation

  • Consider sample collection timing (ARNTL protein levels vary with circadian phase)

• Blotting protocol refinement:

  • Optimize antibody concentration through titration experiments

  • Extend primary antibody incubation time (overnight at 4°C may improve signal)

  • Adjust blocking conditions to minimize background (test different blocking agents)

  • Increase washing stringency to reduce non-specific binding

• Detection optimization:

  • Consider high-sensitivity detection reagents for low-abundance targets

  • Adjust exposure times based on signal intensity

  • Evaluate alternative visualization methods (chemiluminescence vs. fluorescence)

The Picoband® ARNTL antibody is specifically designed to provide high affinity and strong signals with minimal background in Western blot applications, making it particularly suitable for challenging samples .

What are the validated applications for different ARNTL antibody clones?

ARNTL antibodies vary in their validated applications based on their design and epitope targeting:

• Anti-BMAL1/ARNTL Antibody Picoband® (A00260-3) is validated for:

  • Western blot (WB) applications in human, mouse, and rat samples

  • ELISA detection systems

While immunohistochemistry (IHC) applications are not explicitly validated for some commercial antibodies, researchers have successfully used these reagents for brain tissue staining, suggesting broader applicability than the manufacturer's stated applications . When extending to non-validated applications, preliminary testing with appropriate controls is essential to confirm specificity and optimize protocols for the specific tissue and application.

How can researchers accurately quantify ARNTL expression changes in response to experimental interventions?

For accurate quantification of ARNTL expression changes:

• mRNA quantification:

  • Employ RT-PCR with validated primers spanning exon-exon junctions

  • Include reference genes stable under your experimental conditions

  • Consider circadian-time-matched controls to account for natural rhythmicity

• Protein quantification:

  • Use Western blot with densitometry, normalizing to loading controls

  • Consider antibodies with validated linear response ranges

  • Implement replicate blots to account for technical variability

• Integrated approaches:

  • Correlate protein levels (detected by antibodies) with mRNA expression

  • Complement with functional assays (e.g., binding to E-box elements)

  • Validate key findings using orthogonal detection methods

When ARNTL was overexpressed in TSCC HN6 cells, RT-PCR and Western blot confirmed significantly higher ARNTL mRNA and protein levels in the ARNTL-OE group compared to controls (p < 0.05) . This multi-level validation approach provides stronger evidence for successful experimental manipulation.

How can ARNTL antibodies contribute to understanding the connection between circadian rhythms and cancer?

ARNTL antibodies are instrumental in elucidating the molecular mechanisms connecting circadian disruption to cancer development:

• Diagnostic potential:

  • Assess ARNTL expression patterns in tumor vs. adjacent normal tissues

  • Correlate expression levels with clinical outcomes and treatment responses

  • Evaluate ARNTL as a potential prognostic biomarker

• Mechanistic investigations:

  • Study how ARNTL regulates autophagy in cancer cells using transmission electron microscopy and autophagy markers

  • Examine ARNTL interaction with cancer-related signaling pathways

  • Investigate how environmental circadian disruption affects ARNTL-dependent tumor suppression

• Therapeutic implications:

  • Screen for compounds that modulate ARNTL expression or activity

  • Assess chronotherapy approaches based on ARNTL expression patterns

  • Evaluate combination therapies targeting both circadian and cancer pathways

Recent research demonstrates that ARNTL inhibits oral cancer cell proliferation and induces apoptosis through autophagy regulation, providing a promising direction for therapeutic development .

What considerations are important when using ARNTL antibodies in multi-omics approaches?

When integrating ARNTL antibody-based detection into multi-omics research:

• Sample preparation compatibility:

  • Design protocols that allow for parallel -omics analyses from the same sample

  • Consider preservation methods compatible with both protein detection and nucleic acid integrity

  • Document circadian time points precisely for temporal correlation across datasets

• Data integration strategies:

  • Develop computational approaches to correlate antibody-detected protein levels with:

    • Transcriptomic data (RNA-seq or microarray)

    • Epigenomic modifications (ChIP-seq with ARNTL antibodies)

    • Metabolomic changes in pathways regulated by ARNTL

• Validation across platforms:

  • Confirm key findings with orthogonal methods

  • Address potential discrepancies between protein and mRNA levels

  • Consider post-translational modifications that may affect antibody detection

Multi-omics approaches can provide comprehensive insights into how ARNTL regulates complex biological processes like autophagy in cancer cells, as demonstrated in recent research .